Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

355 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Isolated limb perfusion for malignant melanoma.
Alexander HR Jr, Fraker DL, Bartlett DL. Alexander HR Jr, et al. Among authors: bartlett dl. Semin Surg Oncol. 1996 Nov-Dec;12(6):416-28. doi: 10.1002/(SICI)1098-2388(199611/12)12:6<416::AID-SSU7>3.0.CO;2-D. Semin Surg Oncol. 1996. PMID: 8914206 Review.
Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma.
Ma GY, Bartlett DL, Reed E, Figg WD, Lush RM, Lee KB, Libutti SK, Alexander HR. Ma GY, et al. Among authors: bartlett dl. Cancer J Sci Am. 1997 May-Jun;3(3):174-9. Cancer J Sci Am. 1997. PMID: 9161783 Clinical Trial.
Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics.
Bartlett DL, Ma G, Alexander HR, Libutti SK, Fraker DL. Bartlett DL, et al. Cancer. 1997 Dec 1;80(11):2084-90. doi: 10.1002/(sici)1097-0142(19971201)80:11<2084::aid-cncr7>3.0.co;2-x. Cancer. 1997. PMID: 9392330
Isolated hepatic perfusion: a potentially effective treatment for patients with metastatic or primary cancers confined to the liver.
Alexander HR Jr, Bartlett DL, Libutti SK. Alexander HR Jr, et al. Among authors: bartlett dl. Cancer J Sci Am. 1998 Jan-Feb;4(1):2-11. Cancer J Sci Am. 1998. PMID: 9467038 Review. No abstract available.
Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver.
Alexander HR Jr, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Alexander HR Jr, et al. Among authors: bartlett dl. J Clin Oncol. 1998 Apr;16(4):1479-89. doi: 10.1200/JCO.1998.16.4.1479. J Clin Oncol. 1998. PMID: 9552055 Clinical Trial.
Advances in the early detection, diagnosis, and staging of pancreatic cancer.
Riker A, Libutti SK, Bartlett DL. Riker A, et al. Among authors: bartlett dl. Surg Oncol. 1997 Nov;6(3):157-69. doi: 10.1016/s0960-7404(97)00025-x. Surg Oncol. 1997. PMID: 9576631 Review.
A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis.
Bartlett DL, Buell JF, Libutti SK, Reed E, Lee KB, Figg WD, Venzon DJ, Alexander HR. Bartlett DL, et al. Cancer. 1998 Sep 15;83(6):1251-61. Cancer. 1998. PMID: 9740093 Clinical Trial.
Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms.
Alexander HR, Brown CK, Bartlett DL, Libutti SK, Figg WD, Raje S, Turner E. Alexander HR, et al. Among authors: bartlett dl. Clin Cancer Res. 1998 Oct;4(10):2357-62. Clin Cancer Res. 1998. PMID: 9796965
A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer.
Steller MA, Egorin MJ, Trimble EL, Bartlett DL, Zuhowski EG, Alexander HR, Dedrick RL. Steller MA, et al. Among authors: bartlett dl. Cancer Chemother Pharmacol. 1999;43(2):106-14. doi: 10.1007/s002800050870. Cancer Chemother Pharmacol. 1999. PMID: 9923815 Clinical Trial.
Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis.
Cho HK, Lush RM, Bartlett DL, Alexander HR, Wu PC, Libutti SK, Lee KB, Venzon DJ, Bauer KS, Reed E, Figg WD. Cho HK, et al. Among authors: bartlett dl. J Clin Pharmacol. 1999 Apr;39(4):394-401. doi: 10.1177/00912709922007967. J Clin Pharmacol. 1999. PMID: 10197298 Clinical Trial.
355 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback